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After BVS After KB inﬂation p
Proximal BVS area 7.481.73 7.951.99 0.03
AI at proximal stent 0.850.06 0.860.05 0.93
Before SB origin area
(mm2)
6.701.99 7.532.04 <0.01
AI before SB origin 0.810.08 0.800.07 0.88
After SB origin BVS area
(mm2)
6.031,76 5.891.67 0.77
AI after SB origin 0,850,06 0,820,07 0.04
Distal BVS area (mm2) 6.992,03 7,011,72 0.98
AI at distal BVS 0,840,06 0,840,05 0.71
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Background: Everolimus-eluting ABSORB Bioresorbable vascular scaffolds con-
sisted of poly-lactide are programmed to bioresorb approximately in three years. It is
still unknown how the struts implanted in front of a side branch behave during bio-
resorption. The purpose of this study was to assess the fate of bioresorbable struts
jailing side branch ostia at 6, 24 months (cohort B1) or at 12 and 36 months after
implantation of the BVS (cohort B2), with three-dimensional (3-D) optical coherence
tomography (OCT) reconstruction.
Methods: The ABSORB Cohort B trial is a multicentre single-arm trial to assess the
safety and performance of the BVS. Fourier domain-OCT pullbacks were obtained at
a pullback speed of 20 mm/s and 3-D rendering are computed. The area and the
number of strut-free compartments at side branch ostium delineated by the BVS struts
were evaluated. The endo- and abluminal coverages of the struts present at the ostium
of sidebranch were quantiﬁed at 6, 12, 24 and 36 month follow-up.
Results: Serial 3D-OCT images were available in total 26 side branches (13 in cohort
B1 and 13 in cohort B2). In the Cohort B1, the number of compartment and average
ostium area free from jailing struts did not change from baselines to 6 months, but
signiﬁcantly reduced from 6 months to 2 years. In the Cohort B2, there was similarly
a reduction of the number of compartments and the ostium area from baseline to one
year. However, from one year to 3 years, there was late enlargement of the sidebranch
ostium area (1Y: 0.470.64mm2, 3Y: 0.680.38mm2) without changing the number
of compartment. The thickness of the strut coverage was greater at the abluminal
surface compared to endoluminal strut side at followup.
Conclusions: The ostial area jailed by bioresorbable scaffold decreased up to 2 years
due to growing tissue between the struts, but late ostium area enlargement was
observed at 3 years.
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Background: In vitro and in vivo geometry of metallic single stent implantation in
coronary bifurcated lesions after kissing balloon (KB) intervention, has been well
studied. The same analysis of bioabsorbable vascular scaffolding (BVS) had not yetB12 JACC Vol 62/18/Suppl B j October 27–Novembeen reported. Our own in vitro observations with BVS showed integrity and no
device fracture after KB inﬂation when a 2.5 mm balloon diameter was inﬂated
through the struts.
Methods: In our series, 80 coronary bifurcated lesions were treated with provi-
sional BVS strategy. In 21 out of 80 lesions, we performed ﬁnal KB inﬂation after
BVS implantation. The reason for side branch (SB) intervention was ostial
angiographic stenosis (present before BVS implantation in 14 lesions, and
appearing after it in 7). IVUS studies were performed in 3 conditions: before
treatment, immediately after BVS and after KB inﬂation. Measurements were
performed at the proximal scaffold segment, before SB origin, under SB origin and
at the distal segment. This study analyzes the ultrasonographic (IVUS) ﬁndings
after BVS implantation and after KB inﬂation. For KB technique, the balloon
diameter inﬂated in the MV was always 0.5 mm minor than BVS diameter and the
SB balloon diameter was 2 or 2.5 mm.
Results: BVS diameter was 3.10  0.39 mm and the mean inﬂation pressure was
151 atm. The MV balloon diameter was 2.80.3 mm (0.5 mm minor than BVS
diameter in all cases). The SB balloon diameter was 2.30.2 mm and the inﬂation
pressure of both balloons was 7-8 atm. Integrity of the device was always observed
after KB. Good aposition of the proximal BVS and angiographic improvement of the
SB origin was always obtained. Geometry of the BVS may be modiﬁed after KB
technique, but nor distorted. The table summarizes the ﬁndings.Conclusions: Final KB inﬂation in bifurcated coronary lesions treated with BVS is
feasible, without inducing fracture or important distortion of the scaffold.
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Background: The aim of this study was to evaluate clinical outcomes of diabetic
versus non-diabetics patients when treated with the Absorb Bioresorbable Vascular
Scaffold (BVS) at 1-year follow-up.
Methods: This interim post-hoc analysis included 101 patients of the ABSORB
Cohort B trial and the ﬁrst consecutive 450 patients of the ABSORB EXTEND
trial with at least 1-year follow-up. These 2 trials had similar inclusion and
exclusion criteria; 136 diabetic patients were compared to 415 non-diabetic
patients. Primary end point was assessed by a composite of major adverse cardiac
events (MACE), including cardiac death, myocardial infarction, and target lesion
revascularization.
Results: There were no signiﬁcant differences in baseline patient demographics and
lesion characteristics between diabetic and non-diabetic patients treated with the
Absorb BVS, except for the prevalence of hypertension requiring medications
(75.0% in diabetics vs. 61.4% in non-diabetics, p¼0.004). The cumulative incidence
of MACE did not differ between diabetic and non-diabetic patients treated with the
Absorb BVS at 1-year follow-up (3.7% vs. 5.1%, p¼0.64). One patient out of 136
diabetic patients experienced deﬁnite late scaffold thrombosis (ST), whereas four ST
events (1 deﬁnite and 1 probable subacute ST, and 1 deﬁnite and 1 possible late ST)
were observed in the 415 non-diabetic patients. The incidence rate of deﬁnite/
probable ST was thus 0.7% in diabetic group and 0.7% in non-diabetic group
(p¼1.0).ber 1, 2013 j TCT Abstracts/ORAL/Bioabsorbable Vascular Scaffolds
